Impact of the 2013 French Pill Crisis on Women’s Behaviour Regarding Contraception

Drugs - Real World Outcomes

Volumn 2, Issue 1, 2015, Pages 13-22

  Lemaitre, Magali ^a   Lastennet, Glenn ^a   Syr, David ^b   Emmerich, Joseph ^a   Zureik, Mahmoud ^a  

^a French National Agency for Medicines and Health Products Safety   (France)

^b Celtipharm   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRACEPTIVE AGENT; ESTROGEN; ORAL CONTRACEPTIVE AGENT; PROGESTERONE;

ADOLESCENT; ADULT; BEHAVIOR; CONTRACEPTION; EMERGENCY CONTRACEPTION; FEMALE; FRENCHMAN; HUMAN; INTERPERSONAL COMMUNICATION; INTRAUTERINE CONTRACEPTIVE DEVICE; LEVONORGESTREL RELEASING INTRAUTERINE SYSTEM; MIDDLE AGED; PRIORITY JOURNAL; REVIEW; TREND STUDY; VAGINA RING; WOMEN'S HEALTH; YOUNG ADULT;

EID: 84940886549     PISSN: 21991154     EISSN: 21989788     Source Type: Journal    
DOI: 10.1007/s40801-015-0011-z     Document Type: Review

References (28)

1. Barritt DW, Jordan SC. Clinical features of pulmonary embolism. Lancet. 1961;1(7180):729–32.
2. Boyce J, Fawcett JW, Noall EW. Coronary thrombosis and conovide. Lancet. 1963;1(7272):111.
3. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet. 1995;346(8990):1582–8.
4. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet. 1995;346(8990):1589–93.
5. Spitzer WO, Lewis MA, Heinemann LA, Thorogood M, MacRae KD. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case–control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ. 1996;312(7023):83–8.
6. Barnett J, Breakwell GM. The social amplification of risk and the hazard sequence: the October 1995 OC pill scare. Health Risk Soc. 2003;5(3):301–13.
7. European Medicines Agency. Position statement: CPMP concludes its assessment of ‘third generation’ combined oral contraceptives and the risk of venous thromboembolism [document reference: EMEA/CPMP/2250/01/en/Final]. 2001. http://www.ema.europa.eu/docs/en_GB/document_library/Position_statement/2009/12/WC500017650.pdf. Accessed 16 Jan 2015.
8. Jick SS, Hernandez RK. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case–control study using United States claims data. BMJ. 2011;342:d2151.
9. Lidegaard O, Lokkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ. 2009;339:b2890.
10. Lidegaard O, Nielsen LH, Skovlund CW, Skjeldestad FE, Lokkegaard E. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001–9. BMJ. 2011;343:d6423.
11. Austin H, Lally C, Benson JM, Whitsett C, Hooper WC, Key NS. Hormonal contraception, sickle cell trait, and risk for venous thromboembolism among African American women. Am J Obstet Gynecol. 2009;200(6):620 e1–3.
12. Parkin L, Sharples K, Hernandez RK, Jick SS. Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case–control study based on UK General Practice Research Database. BMJ. 2011;342:d2139.
13. European Medicines Agency. Pharmacovigilance Working Party (PhVWP): May 2011 plenary meeting [document reference: EMA/CHMP/PhVWP/394737/2011]. 2011. http://www.ema.europa.eu/docs/en_GB/document_library/Report/2011/05/WC500106708.pdf. Accessed 16 Jan 2015.
14. Haute Autorité de Santé. Contraceptifs oraux estroprogestatifs: préférez les «pilules» de 1re ou 2e génération—fiche BUM. 2012. http://www.has-sante.fr/portail/jcms/r_1439689/fr/contraceptifs-oraux-estroprogestatifs-preferez-les-pilules-de-1re-ou-2e-generation-fiche-bum. Accessed 16 Jan 2015.
15. Agence Nationale d’Accréditation et d’Évaluation en Santé. Recommandations pour la pratique clinique. Stratégies de choix des méthodes contraceptives chez la femme: recommandations. 2004. http://www.choisirsacontraception.fr/pdf/contraception_recommandations_has.pdf. Accessed 16 Jan 2015.
16. Haute Autorité de Santé. Réévaluation des contraceptifs oraux de troisième génération (annexe commune)—juin 2012. 2012. http://www.has-sante.fr/portail/jcms/c_1322400/fr/reevaluation-des-contraceptifs-oraux-de-troisieme-generation-annexe-commune-juin-2012. Accessed 16 Jan 2015.
17. Tricotel A, Raguideau F, Collin C, Zureik M. Estimate of venous thromboembolism and related-deaths attributable to the use of combined oral contraceptives in France. PLoS One. 2014;9(4):e93792.
18. Celtipharm. Secondary real-time health data for sustainable care. http://www.xpr-so.com/pages/Public/Accueil.aspx. Accessed March 2014.
19. Kish J. Survey sampling. New York: Wiley; 1965.
20. Pivette M, Mueller JE, Crepey P, Bar-Hen A. Surveillance of gastrointestinal disease in France using drug sales data. Epidemics. 2014;8:1–8.
21. Crepey P, Pivette M, Bar-Hen A. Quantitative assessment of preventive behaviors in France during the Fukushima nuclear crisis. PLoS One. 2013;8(3):e58385.
22. Pivette M, Mueller JE, Crepey P, Bar-Hen A. Drug sales data analysis for outbreak detection of infectious diseases: a systematic literature review. BMC Infect Dis. 2014;14(1):604.
23. Lidegaard O, Nielsen LH, Skovlund CW, Lokkegaard E. Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001–10. BMJ. 2012;344:e2990.
24. Blin P, Lassalle R, Dureau-Pournin C, et al. Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database. Diabetologia. 2012;55(3):644–53.
25. Bongue B, Laroche ML, Gutton S, et al. Potentially inappropriate drug prescription in the elderly in France: a population-based study from the French National Insurance Healthcare system. Eur J Clin Pharmacol. 2011;67(12):1291–9.
26. Sidney S, Cheetham TC, Connell FA, et al. Recent combined hormonal contraceptives (CHCs) and the risk of thromboembolism and other cardiovascular events in new users. Contraception. 2013;87(1):93–100.
27. Dinger J, Mohner S, Heinemann K. Cardiovascular risk associated with the use of an etonogestrel-containing vaginal ring. Obstet Gynecol. 2013;122(4):800–8.
28. Moreau C, Bohet A, Hassoun D, Teboul M, Bajos N. Trends and determinants of use of long-acting reversible contraception use among young women in France: results from three national surveys conducted between 2000 and 2010. Fertil Steril. 2013;100(2):451–8.